Literature DB >> 3355794

Variation in clinical severity among patients with Hb Lepore-Boston-beta-thalassaemia is related to the type of beta-thalassaemia.

D G Efremov1, G D Efremov, N Zisovski, N Stojanovski, F Kutlar, J C Diaz-Chico, A Kutlar, K G Yang, T A Stoming, T H Huisman.   

Abstract

Clinical and haematological observations, made for 10 Yugoslavian patients with the Hb Lepore-beta-thalassaemia condition, suggested a considerable variation from severe disease and complete blood transfusion dependency to a moderate, compensated, anaemia without major complications and without a need for regular blood transfusions. As the type of Hb Lepore was the same in all patients (Lepore-Boston-Washington) and an alpha-globin gene deficiency was absent, it was concluded that the type of beta-thalassaemia determined the severity of the disease. Six patients with severe disease had one of the following three beta-thalassaemia determinants: IVS-1 position 110 G----A, exon 2 codon 39 C----T, and IVS-1 position 1 G----A, while the three patients with mild disease had the Portuguese type of thalassaemia which is caused by the T----C substitution at position 6 of the IVS-1. In one patient with severe disease the beta-thalassaemia determinant remained unknown. Our observations are consistent with those made for thalassaemia patients with a homozygosity for these determinants.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3355794     DOI: 10.1111/j.1365-2141.1988.tb04213.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Biochemical and Molecular Analysis of the Hb Lepore Boston Washington in a Syrian Homozygous Child.

Authors:  Monica Pirastru; Laura Manca; Sandro Trova; Paolo Mereu
Journal:  Biomed Res Int       Date:  2017-05-03       Impact factor: 3.411

2.  Genetics in Macedonia-Following the international trends.

Authors:  Elena Sukarova-Angelovska; Aleksandar Petlichkovski
Journal:  Mol Genet Genomic Med       Date:  2018-02-20       Impact factor: 2.473

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.